Huperzine A is a natural cholinesterase inhibitor, taken from the Chinese herb Huperzia Serrata. There are suggestions that Huperzine A is similar in symptomatic efficacy to currently practiced cholinesterase inhibitors.

Furthermore, it has antioxidant and neuroprotective properties, advising that it may be useful as a modifying procedure for Alzheimer’s disease (AD).  Currently, the drug is accessible as a nutraceutical in this nation and is used by some doctors in the United States to treat Alzheimer’s disease.

However, no controlled clinical trial outside of China has evaluated toxicity and ability. In the present study, Huperzine A in the treatment of Alzheimer’s disease is considered in randomized controlled research to define its effect.

The main purpose of this phase II, multicenter, placebo-controlled is to decide if treatment with Huperzine A 200 g double a day develops cognitive function in people with Alzheimer’s disease. The subsidiary objectives of this research are:

  • to decide if proceeding with Huperzine A 400 g double a day progresses cognitive function in individuals with Alzheimer’s disease.
  • Discover the effect of Huperzine A treatment on general clinical trials, daily activities, and behavior in Alzheimer’s disease.
  • Evaluation of the tolerability of dealing with Huperzine A at a dose of 200 g double a day and 400 g double a day for AD;
  • Also, determine the association between blood cholinesterase action and cognitive reception in individuals with Alzheimer’s disease and approached with Huperzine A.

A total of 150 associates are randomly distributed to three combinations of the same size. This distinguishes Huperzine A 200g double daily, Huperzine A 400g twice every day, and a placebo. The main activity will be to transform the ADAScog score through the 16-week visit.

Missionaries must be able to join in the study for 24 weeks and make 9 visits to the experiment site. At the end of the second-blind study, members are advised to resume Huperzine A.